Skip to main content
Premium Trial:

Request an Annual Quote

Ambit, Cephalon Pen Kinase Drug-Discovery, Development Alliance

NEW YORK (GenomeWeb News) — Ambit Biosciences today said it will combine its KinomeScan-driven discovery technology with Cephalon's chemistry and discovery and development chops to help develop kinase inhibitors.
 
Terms of the deal call for Ambit to screen a “large” library of Cephalon’s kinase-focused compounds to generate “nearly a million data points,” Ambit said. In return, Cephalon will pay Ambit $18 million in an up-front fee to access its KinomeScan technology.
 
The companies will also partner in two programs targeting undisclosed kinases. Terms of those deals give Ambit the responsibility for delivering clinical candidates that Cephalon will further develop in exchange for $232.5 million in additional milestones to Ambit, as well as royalties.
 
Ambit will also use Cephalon library compounds to discover and develop products that are effective inhibitors of certain undisclosed kinases, the company said.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.